Literature DB >> 28954901

Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples.

Lance R Peterson1, Stephen A Young2,3, Thomas E Davis4, Zi-Xuam Wang5, John Duncan6, Christopher Noutsios6, Oliver Liesenfeld6, John C Osiecki6, Michael A Lewinski6.   

Abstract

Nucleic acid amplification tests (NAATs) are reliable tools for the detection of toxigenic Clostridium difficile from unformed (liquid or soft) stool samples. The objective of this study was to evaluate performance of the cobas Cdiff test on the cobas 4800 system using prospectively collected stool specimens from patients suspected of having C. difficile infection (CDI). The performance of the cobas Cdiff test was compared to the results of combined direct and broth-enriched toxigenic culture methods in a large, multicenter clinical trial. Additional discrepancy analysis was performed by using the Xpert C. difficile Epi test. Sample storage was evaluated by using contrived and fresh samples before and after storage at -20°C. Testing was performed on samples from 683 subjects (306 males and 377 females); 113 (16.5%) of 683 subjects were positive for toxigenic C. difficile by direct toxigenic culture, and 141 of 682 subjects were positive by using the combined direct and enriched toxigenic culture method (reference method), for a prevalence rate of 20.7%. The sensitivity and specificity of the cobas Cdiff test compared to the combined direct and enriched culture method were 92.9% (131/141; 95% confidence interval [CI], 87.4% to 96.1%) and 98.7% (534/541; 95% CI, 97.4% to 99.4%), respectively. Discrepancy analysis using results for retested samples from a second NAAT (Xpert C. difficile/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test results. There was no difference in positive and negative results in comparisons of fresh and stored samples. These results support the use of the cobas Cdiff test as a robust aid in the diagnosis of CDI.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Clostridium difficile infection (CDI); active surveillance testing (AST); health care-associated infection; nucleic acid amplification test; toxin B (tcdB) gene

Mesh:

Substances:

Year:  2017        PMID: 28954901      PMCID: PMC5703809          DOI: 10.1128/JCM.01135-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Supplementary testing is not required in the cobas 4800 CT/NG test for Neisseria gonorrhoeae weak-positive urogenital samples.

Authors:  Collette Bromhead; Nadika Liyanarachchy; Julia Mayes; Arlo Upton; Michelle Balm
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 2.  Clostridium difficile.

Authors:  Scott R Curry
Journal:  Clin Lab Med       Date:  2017-03-22       Impact factor: 1.935

3.  Comparison of cobas 4800, m2000, Viper XTR, and Infinity 80 Automated Instruments When Processing Urine Specimens for the Diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Max A Chernesky; Dan Jang; Jodi Gilchrist; Marek Smieja; Manuel Arias; Todd Hatchette; Andre Poirier; Donna Mayne; Sam Ratnam
Journal:  Sex Transm Dis       Date:  2017-03       Impact factor: 2.830

4.  International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants.

Authors:  Stuart Johnson; Susan P Sambol; Jon S Brazier; Michel Delmée; V Avesani; Michelle M Merrigan; Dale N Gerding
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Workflow and maintenance characteristics of five automated laboratory instruments for the diagnosis of sexually transmitted infections.

Authors:  Sam Ratnam; Dan Jang; Jodi Gilchrist; Marek Smieja; Andre Poirier; Todd Hatchette; Jean-Frederic Flandin; Max Chernesky
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

Review 6.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

7.  Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.

Authors:  Alexandre Harlé; Benoit Busser; Marie Rouyer; Valentin Harter; Pascal Genin; Agnès Leroux; Jean-Louis Merlin
Journal:  Virchows Arch       Date:  2013-02-12       Impact factor: 4.064

8.  Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.

Authors:  Samia Mourah; Marc G Denis; Fabienne Escande Narducci; Jérôme Solassol; Jean-Louis Merlin; Jean-Christophe Sabourin; Jean-Yves Scoazec; L'Houcine Ouafik; Jean-François Emile; Remy Heller; Claude Souvignet; Loïc Bergougnoux; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 9.  Current knowledge on the laboratory diagnosis of Clostridium difficile infection.

Authors:  Adrián Martínez-Meléndez; Adrián Camacho-Ortiz; Rayo Morfin-Otero; Héctor Jesús Maldonado-Garza; Licet Villarreal-Treviño; Elvira Garza-González
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

10.  Performance of the cobas MRSA/SA Test for Simultaneous Detection of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus From Nasal Swabs.

Authors:  Lance R Peterson; Christopher W Woods; Thomas E Davis; Zi-Xuam Wang; Stephen A Young; John C Osiecki; Michael A Lewinski; Oliver Liesenfeld
Journal:  Am J Clin Pathol       Date:  2017-08-01       Impact factor: 2.493

View more
  6 in total

1.  Validation of Active Surveillance Testing for Clostridium difficile Colonization Using the cobas Cdiff Test.

Authors:  Parul A Patel; Donna M Schora; Kamaljit Singh; Lance R Peterson
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 2.  Laboratory Tests for the Diagnosis of Clostridium difficile.

Authors:  Karen C Carroll; Masako Mizusawa
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

3.  Equivalent Performance of the Cobas® Cdiff Test for Use on the Cobas® Liat® System and the Cobas® 4800 System.

Authors:  Sachin K Garg; Kyle Lu; John Duncan; Lance R Peterson; Oliver Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-12-05

4.  Diagnostic test evaluation methodology: A systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard - An update.

Authors:  Chinyereugo M Umemneku Chikere; Kevin Wilson; Sara Graziadio; Luke Vale; A Joy Allen
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

5.  Laboratory Diagnostic Methods for Clostridioides difficile Infection: the First Systematic Review and Meta-analysis in Korea.

Authors:  Hae-Sun Chung; Jeong Su Park; Bo-Moon Shin
Journal:  Ann Lab Med       Date:  2021-03-01       Impact factor: 3.464

6.  Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection.

Authors:  Paul A Granato; Glen Hansen; Emily Herding; Sheena Chaudhuri; Shaowu Tang; Sachin K Garg; Catherine R Rowell; Joanna Jackson Sickler
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.